Phase 3 N=185 Efficacy and Safety Study of Caldolor (IV Ibuprofen) in Hospitalized Adult Orthopedic Patients
Pain
Primary: AUC-VAS With Movement (Post-operative Period, Hour-6-28) — 1326.1; 1005.0 AUC-VAS pain v. time (mm*hr)
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=274 Testosterone Treatment for Hypogonadal Men
Hypogonadism
Primary: Percentage of Subjects on Testosterone Treatment Achieving Target Range for Testosterone Cav (Time-averaged Concentration Over the Dosing Interval of 24 Hours) on Day…
Phase 3 N=572 A Study of the Safety and Effectiveness of Sativex®, for the Relief of Symptoms of Spasticity in Subjects, From Phase B, With Multiple Sclerosis (MS)
Spasticity · Multiple Sclerosis
Primary: The Change in Mean Spasticity Numerical Rating Scale (NRS) Score From Baseline to End of Treatment (Phase B). — 3.68; 4.56 Points on scale — p=0.0002
Phase 3 N=610 Efficacy Study of PN400 (VIMOVO) Twice Daily and Celebrex Once Daily in Patients With Osteoarthritis
Osteoarthritis
Primary: Change in Western Ontario and McMaster Universities (WOMAC) Pain Questionnaire Subscore From Baseline — -44.1; -43.6; -37.3 mm
Phase 3 N=50 Evaluation of Screening Methods for Treatment of Meibomian Gland Dysfunction
Chalazion · Dry Eye Syndromes
Primary: Association Between Screening Methods (Meibomian Gland Expression) and Treatment Effectiveness Outcomes (Total Meibomian Gland Score) — 0.4816 Correlation coefficient…
Phase 3 N=370 A Study of Mycophenolate Mofetil (CellCept) in Management of Patients With Lupus Nephritis.
Lupus Nephritis
Primary: Induction Phase: Number of Patients Showing Treatment Response — 98; 104; 87; 81 participants — p=0.478
Phase 3 N=470 Efficacy and Safety of Insulin Detemir Versus Neutral Protamine Hagedorn (NPH) Insulin in Pregnant Women With Type 1 Diabetes
Diabetes · Diabetes Mellitus, Type 1
Primary: Glycosylated Haemoglobin (HbA1c) for Full Analysis Set (Pregnant Subjects) at GW 36 — 6.27; 6.33 Percent (%) glycosylated haemoglobin — p=0.400
Phase 3 N=652 A Phase III Study of Abatacept (BMS-188667) in Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate
Rheumatoid Arthritis
Primary: Number of American College of Rheumatology 20 (ACR 20) Responders at Day 169 — 288; 85 Participants — p=<0.001
Phase 3 N=244 Peginterferon α-2b as a Maintenance Therapy in Participants With Multiple Myeloma Who Responded to Induction Therapy (P01972-AM7)
Multiple Myeloma
Primary: Number of Days With Progression Free Survival (PFS) — 1166; 519 Days
Phase 3 N=149 Open-Label Extension Study for Patients Who Completed a Phase 3 Double-blind Study of PEG-uricase for Symptomatic Gout
Gout
Primary: Uric Acid (mg/dL) — 1.33; 1.91; 5.06; 9.76 mg/dL
Phase 3 N=102 Efficacy and Safety of Peginterferon Alfa-2b and Ribavirin Therapy in Subjects With Type C Compensated Liver Cirrhosis (Study P05116)
Hepatitis C, Chronic · Liver Cirrhosis
Primary: Number of Participants With Undetectable HCV-RNA at Week 72 (Sustained Virologic Response) — 41; 40; 21 Participants
Phase 3 N=64 A Study of Synthetic Human Secretin (ChiRhoStim®) Administered Intravenously to Stimulate Exocrine Pancreas Fluid Secretion for Collection Via Endoscope and Laboratory Analysis of DNA Markers
Pancreatic Disease
Primary: Endoscopic Sample
Phase 3 N=19 Clinical Evaluation of Eltrombopag in Chronic Idiopathic Thrombocytopenic Purpura (ITP)
Idiopathic Thrombocytopenic Purpura · Purpura, Thrombocytopenic, Idiopathic
Primary: Number of Participants Experiencing an Adverse Event (AE) and/or Serious Adverse Event (SAE) Within the Indicated Category — 19; 6; 5; 0 participants
Phase 3 N=193 Pediatric Bipolar Depression
Bipolar Depression
Primary: Change in the Children Depression Rating Scale, Revised (CDRS-R) Total Score From Baseline to Final Assessment (Day 57) — -29.6; -27.3 Scores on a scale
Phase 3 N=37 Efficacy and Safety Study of Pamoate of Triptorelin in Children With Precocious Puberty
Precocious Puberty
Primary: Number of Participants With a GnRH-stimulated LH Level ≤3 IU/L — 31; 6; 31; 3 participants